Celldex Therapeutics Inc (CLDX)

Celldex Therapeutics Inc (CLDX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.3B; returns 1 day +1.0%, 1 week +6.2%, 1 year +11.4%.

Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic antibodies to treat severe inflammatory, allergic, and autoimmune diseases. The company's revenue is currently negligible, primarily stemming from manufacturing and research and development agreements, such as with Rockefeller University.

Groups CLDX belongs to

• Biotechnology
• Biopharmaceutical
• Healthcare
• Clinical Stage
• Clinical Stage Biotech
• Clinical Stage Biopharma
• Autoimmune Diseases
• Antibody Therapeutics
• Monoclonal Antibodies
• Dermatology
• Life Sciences
• Chronic Inflammatory Diseases
• Bispecific Antibodies

CLDX financial model: income statement, cash flow and balance sheet